COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance

Nat Commun. 2021 Jun 23;12(1):3903. doi: 10.1038/s41467-021-24078-9.


While mass-scale vaccination campaigns are ongoing worldwide, genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to monitor the emergence and global spread of viral variants of concern (VOC). Here, we present a streamlined workflow-COVseq-which can be used to generate highly multiplexed sequencing libraries compatible with Illumina platforms from hundreds of SARS-CoV-2 samples in parallel, in a rapid and cost-effective manner. We benchmark COVseq against a standard library preparation method (NEBNext) on 29 SARS-CoV-2 positive samples, reaching 95.4% of concordance between single-nucleotide variants detected by both methods. Application of COVseq to 245 additional SARS-CoV-2 positive samples demonstrates the ability of the method to reliably detect emergent VOC as well as its compatibility with downstream phylogenetic analyses. A cost analysis shows that COVseq could be used to sequence thousands of samples at less than 15 USD per sample, including library preparation and sequencing costs. We conclude that COVseq is a versatile and scalable method that is immediately applicable for SARS-CoV-2 genomic surveillance and easily adaptable to other pathogens such as influenza viruses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COVID-19 / blood
  • COVID-19 / economics
  • COVID-19 / genetics*
  • COVID-19 / virology
  • Cells, Cultured
  • Chlorocebus aethiops
  • Cost-Benefit Analysis
  • Epidemiological Monitoring
  • Genome, Viral
  • High-Throughput Nucleotide Sequencing / economics
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Phylogeny
  • SARS-CoV-2 / genetics*
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / pathogenicity
  • Workflow